In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.

J Infect · 2021 · PMC7904476 · PMID 33639176

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Baricitinib does decrease the in vitro viral-specific response in patients with a high lymphocytes count and with mild/moderate COVID-19 and also in the severe and critical cases tested, although in these last the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.